Search for authorsSearch for similar articles
15
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Estudos in vitro e in vivo de análogo da timidina marcada com complexo organometálico de tecnécio-99m para potencial uso em diagnóstico tumoral Translated title: Studies in vitro and in vivo of thymidine analog labeled with organometalic complex of technetium-99m for potential use in tumor diagnosis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Análogos da timidina têm sido marcados com diferentes radioisótopos devido ao seu potencial em monitorar a proliferação incontrolável de células. Considerando que o radioisótopo tecnécio-99m ainda mantém uma posição privilegiada devido às suas propriedades químicas e nucleares, este trabalho constituiu-se no desenvolvimento da marcação da timidina com o 99mTc, mediante o emprego de compostos organometálicos. Os objetivos principais foram a síntese do precursor carbonil-tecnécio-99m, marcação da timidina com este precursor, estudo da estabilidade, e avaliações radioquímicas e biológicas com animais sadios e portadores de tumor. A síntese do precursor organometálico e a marcação da timidina com este precursor foi realizada com > 97% e > 94% de pureza radioquímica, respectivamente, obtendo-se também uma boa estabilidade em até 6 h em temperatura ambiente. A transquelação frente aos aminoácidos cisteína e histidina apresentou perdas entre 8 e 11% para concentrações de até 300 mM. Os ensaios de biodistribuição em camundongos sadios indicaram que o complexo radiomarcado apresentou um rápido depuramento sangüíneo e baixa captação nos demais órgãos, com predominância de excreção da droga pelo sistema urinário e hepatobiliar. A captação tumoral foi de 0,28 e 0,18 %DI/g para tumor de pulmão e mama, respectivamente. Os resultados obtidos sugerem maiores investigações em outros análogos da timidina.

          Translated abstract

          Thymidine analogs have been labeled with different radioisotopes due to their potential in monitoring the uncontrollable cell proliferation. Considering that the radioisotope technetium-99m still keeps a privileged position as a marker due to its chemical and nuclear properties, this work was designed to develop a new technique of labeling of thymidine analog with 99mTc, by means of the organometallic compounds. The aims of this research were: synthesis of the organometallic precursor technetium-99m-carbonyl, thymidine labeling with this precursor, study of stability, and radiochemical e biological evaluation with healthy and tumor-bearing animals. The organometallic precursor and the labeling of thymidine with this precursor were resulted with a radiochemical pureness of > 97% and > 94%, respectively, with good radiochemical stability up to 6 h in room temperature. The cysteine and histidine challenge indicated losses between 8 and 11% for concentrations until 300 mM. The biodistribution assay in healthy mice revealed rapid blood clearance and low uptake by general organs with renal and hepatobiliary excretion. The tumor concentration was of 0.28 and 0.18 %ID/g for lung and breast cancer, respectively. The results imply more studies in other thymidine analogs.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: not found
          • Article: not found

          A Novel Organometallic Aqua Complex of Technetium for the Labeling of Biomolecules:  Synthesis of [99mTc(OH2)3(CO)3]+from [99mTcO4]-in Aqueous Solution and Its Reaction with a Bifunctional Ligand

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Imaging proliferation in vivo with [F-18]FLT and positron emission tomography.

            Positron emission tomography (PET) is now regularly used in the diagnosis and staging of cancer. These uses and its ability to monitor treatment response would be aided by the development of imaging agents that can be used to measure tissue and tumor proliferation. We have developed and tested [F-18]FLT (3'-deoxy-3'-fluorothymidine); it is resistant to degradation, is retained in proliferating tissues by the action of thymidine kinase 1 (TK), and produces high-contrast images of normal marrow and tumors in canine and human subjects.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Current use and future potential of organometallic radiopharmaceuticals.

              Contrary to common belief, organometallic compounds exhibit remarkable stability in aerobic and even diluted aqueous solutions. Technetium-sestamibi (Cardiolite) is one of the most prominent examples of this class of compounds routinely used in nuclear medicine. This review summarises the recent progress in labelling of biomolecules with organometallic complexes for diagnostic and therapeutic application in radiopharmacy and exemplifies in detail developments focussing on organometallic technetium- and rhenium-tricarbonyl technologies. The value of such technologies has been recognised and they have become a valuable alternative to common labelling methodologies. An increasing number of groups have started to employ an organometallic precursor for the purpose of radioactive labelling of various classes of biomolecules, and the advantages and limitations of this new technique are compared with those of other labelling methods. The synthetic access to appropriate precursors via double-ligand exchange or aqueous carbonyl kit preparation for routine application is described. Strategies and examples for the design of appropriate bifunctional chelating agents for the Tc/Re-tricarbonyl core are given. The functionalization of biomolecules such as tracers for the central nervous system (dopaminergic and serotonergic), tumour affine peptides (somatostatin receptors, neuroreceptors) and tumour binding single-chain antibody fragments is summarised. Where possible and appropriate, the in vitro and in vivo results in respect of these examples are compared with those obtained with classical (99m)Tc/(188)Re(V)- and (111)In-labelled analogues. The preclinical results show the in many ways superior characteristics of organometallic labelling techniques.
                Bookmark

                Author and article information

                Journal
                rbcf
                Revista Brasileira de Ciências Farmacêuticas
                Rev. Bras. Cienc. Farm.
                Divisão de Biblioteca e Documentação do Conjunto das Químicas da Universidade de São Paulo (São Paulo, SP, Brazil )
                1516-9332
                March 2008
                : 44
                : 1
                : 85-95
                Affiliations
                [01] orgnameCNEN orgdiv1Instituto de Pesquisas Energéticas e Nucleares orgdiv2Centro de Radiofarmácia
                Article
                S1516-93322008000100010 S1516-9332(08)04400110
                501dd0aa-abda-4467-9792-daf6b524e962

                This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

                History
                : 13 October 2007
                : 29 March 2007
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 36, Pages: 11
                Product

                SciELO Brazil

                Categories
                Trabalhos Originais

                Tunor diagnosis,Timidina,Complexo organometálico,Tecnécio-99m,Diagnóstico tumoral,Thymidine,Organometallic complex,Technetium-99m

                Comments

                Comment on this article